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Abstract
Neurotropic tick borne encephalitis virus (TBEV) causes life-threatening disease, and
accounts for most cases of tick-transmitted viral infections in Central and Eastern Europe
and Russia. No specific treatment for TBEV infections exists, and vaccination is recom-
mended for people at risk. So far, various nucleoside analogues have been investigated in
vitro as potential candidates for treatment of TBEV infections. However, in vitro experiments
with more complex cell culture systems, such as organotypic culture slices which model the
sophisticated architecture of the target tissue are lacking. Using TBEV as a model, we inves-
tigated the suitability of rat organotypic cerebellum slices (OCS) to study the effectiveness
of nucleoside analogues with a well-known anti-TBEV activity. In these OCS, 50 μM of the
nucleoside analogues 2’-C-methyladenosine (2’-CMA) and especially 7-deaza-2’-C-methy-
ladenosine (7-deaza-2’-CMA) exhibited strong inhibitory effects on TBEV replication, reduc-
ing viral titers to an average of 103-fold and TBEV RNA content 60-90-fold. In contrast, the
influence of 2’-C-methylcytidine (2’-CMC) on TBEV replication was very weak, reducing
virus titers by 10-fold and TBEV RNA content by 3-fold. In agreement with other studies,
there was no noticeable difference in TBEV titers between OCS treated with 50 μM of Riba-
virin and the DMSO treated controls. All tested nucleoside analogues exhibited excellent
cytotoxicity profiles at concentrations of 50 μM. Our findings in OCS were highly comparable
to data obtained in cell line culture systems. Therefore, OCS represent an ideal in vitro
approach to study antivirals against TBEV and possibly other neurotropic viruses.
Introduction
Tick-borne encephalitis virus (TBEV), a member of the Flaviviridae family, is a single stranded
positive sense RNA virus with a genome of about 11 kb in length. It expresses a single polypro-
tein, which is post-translationally cleaved into 3 structural and 7 nonstructural proteins [1].
The principal vectors of TBEV are ticks, belonging to the Ixodidae family, more specifically
Ixodes ricinus in Central Europe and Ixodes persulcatus in Eastern Europe and Russia [2].
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Small rodents, deer, sheep and goats act as a reservoir for TBEV infection of ticks [3]. TBEV
causes tick borne encephalitis (TBE); a disease caused by the European subtype virus is usually
biphasic. It manifests in the first stage with febrile, flu-like symptoms, whereas in the second
stage TBEV breaches the blood-brain barrier causing serious, potentially life threatening men-
ingitis, encephalitis, meningoencephalitis, meningoencephalomyelitis and radiculitis. 10–20%
of patients suffer from long lasting or permanent neuropsychiatric sequelae [4]. Although vac-
cinations against TBEV exist, TBE is still the most common tick-transmitted viral disease in
Central and Eastern Europe as well as in Russia [3].
No specific antiviral treatment exists thus far, emphasizing the need for a safe and effi-
cacious therapeutic intervention [5]. The mode of action of the largest class of antiviral
drugs relies on inhibition of viral polymerases, for which nucleoside analogues are the
most widely used [6]. Nucleoside analogues against flaviviruses act as inhibitors of RNA-
dependent RNA polymerases (RdRp), methlytransferases, and helicases / nucleosid tri-
phosphatases [7]. Eyer et al. carried out extensive studies investigating different nucleo-
side analogues and their influence on replication of TBEV strains Hypr and Neudoerfl in
porcine kidney stable (PS) and human neuroblastoma cells (UKF-NB-4). 2’-C-methyl
substituents to the nucleoside β-face resulted in the strongest inhibition of TBEV replica-
tion and had excellent cytotoxicity profiles. The most effective candidates were 2’-C-
methyladenosine (2’-CMA), 2’-C-methylcytidine (2’-CMC) and 7-deaza-2’-C-methylade-
nosine (7-deaza-2’-CMA), all of which are inhibitors of the flaviviral RdRp [7–9]. The
therapeutic effect of the most promising candidate, 7-deaza-2’-CMA, was furthermore
tested in a lethal TBE mouse model. Mice treated with 7-deaza-2’-CMA presented with
reduced viral titers in the brain and increased survival rates [10].
Cell lines enable screening of large libraries of antiviral compounds, yet the results vary
considerably between different cell types [11]. Therefore we developed rat organotypic cerebel-
lum slices (OCS), representing the primary target site for TBEV infection in the brain [12].
The natural anatomy of the cerebellum is conserved in OCS. Therefore they closely reproduce
the complex interactions of different cell types which may play an important role in TBEV
infection and treatment. To evaluate the OCS as an in vitro culture model for testing antiviral
substances against neurotropic viruses, we evaluated the previously published inhibitory effect
of the nucleoside analogues 2’-CMA, 2’-CMC, 7-deaza-2’-CMA and Ribavirin on TBEV repli-
cation in OCS. We could confirm the finding by Eyer et al. [8, 9] showing that, treatment with
2’-CMA and 7-deaza-2’-CMA significantly reduced TBEV titers, whereas 2’ CMC resulted in
only minimal reduction. Importantly, all investigated nucleoside analogues exhibited excellent
cytotoxicity profiles in OCS.
Materials and methods
Ethics statement
Animal studies were approved by the Animal Care and Experimentation Committee of the
Canton Bern, Switzerland (No. BE124/13 and BE142/16). Swiss National Guidelines for the
performance of animal experiments were strictly followed.
Porcine kidney stable (PS) cell cultures
PS cells, kindly provided by Daniel Růzˇek (Czech Academy of Sciences, Česke´ Budêjovice,
Czech Republic), were cultured at 37 ˚C in Leibovitz (L-15) medium (Merck Millipore, Biller-
ica, MA, USA) supplemented with 5% fetal calf serum, 1% penicillin-streptomycin and 1% glu-
tamine (Sigma-Aldrich, St. Louis, MO, USA) [13].
Evaluation of antivirals in organotypic cultures
PLOS ONE | https://doi.org/10.1371/journal.pone.0205294 October 9, 2018 2 / 13
Production and maintenance of rat organotypic cerebellum slices (OCS)
Purkinje cells were identified as the main cell type infected by a TBEV model virus in the cerebel-
lum [12]. Since Purkinje cells are most abundant and polarized in the brain of 10 days-old pups
[14], we euthanized 10 days-old Wistar rats (Charles River Laboratories, Sulzfeld, Germany) by a
lethal dose of intraperitoneal pentobarbital (G. Streuli & Cie. SA, Uznach, Switzerland). The brain
was immediately removed and submerged in ice-cold dissection medium (Hanks balanced salt
solution with 1% antibiotic-antimycotic, Gibco Life Technologies, Waltham, MA, USA, and 6mg/
ml glucose, Sigma-Aldrich). The brains were cut in half in the sagittal plane and glued on a sample
tray using Roti Coll Superglue (Carl Roth, Karlsruhe, Germany). To conserve the Purkinje cells’
dendritic trees, the cerebella were cut in 400 μm thin section in the sagittal plane by a Leica
VT1000 S vibratome (Leica Biosystems, Wetzlar, Germany), while being submerged in ice-cold
dissection medium. Four slices were transferred to one Transwell insert consisting of a semipor-
ous (0.4 μm) membrane (Corning Inc., Corning, NY, USA). Inserts were placed in 6 well plates
containing 1 ml serum-free Neurobasal medium (NBM) supplemented with 1% antibiotic-anti-
mycotic, 1% Hepes, 1% Glutamax and 20 μl / ml B27 (Gibco Life Technologies). Slices were incu-
bated at 37 ˚C and 5% CO2 for 9–10 days until further use. The medium was changed on the 1
st
day and then every 2nd-3rd day. For biosafety reasons, infected OCS were kept in a
GenBox containing a CO2 bag to reach 5% CO2 (BioMe´rieux, Marcy-l’E´toile, France) without
medium replacement until the end of the experiment.
Virus strains and antiviral compounds
All experiments were performed with TBEV strain Hypr kindly provided by Daniel Růzˇek
(Czech Academy of Sciences, Česke´ Budêjovice, Czech Republic). 2’-CMA and 7-deaza-2’-
CMA were obtained from Santa Cruz Biotechnology (Dallas, TX, USA), while 2’-CMC and
Ribavirin were from Sigma-Aldrich. The test compounds were solubilized in DMSO (sterile
filtered, suitable for hybridoma, Sigma-Aldrich) to yield 10 mM concentrated stock solutions.
Viral titer reduction assay
OCS were prepared as described above. Each test compound was assessed in 3 independent bio-
logical replicates (3 wells each containing 4 slices). One milliliter of supplemented neurobasal
medium (NBM) containing 50 μl of each test compound at 50 μM (or 50 μl DMSO for the mock
treated wells) and 105 plaque forming units (PFU) of TBEV strain Hypr were used for infection.
One hundred microliters of virus / antiviral solution was added on top of the OCS in droplets,
whereas 900 μl of the solution was added to the bottom of the well. The plates were incubated for
1 h at 37 ˚C with a CO2 bag. The medium was replaced with 1 ml of supplemented NBM contain-
ing 50 μl of each test compound and incubated at 37 ˚C with a new CO2 bag for 72 hrs. Three
OCS in 600 μl of supernatant were transferred to tubes containing ceramic beads with 1.4 mm
diameter (CK14 tubes, Precellys, Bertin Technologies, Montigny-le-Bretonneux, France). The
samples were homogenized at 6500 rpm twice for 25 seconds with a 10 second break. The tubes
were centrifuged for 1 minute at 10’000 g and stored at -80 ˚C. One hundred microliters of
homogenate was directly inactivated in 400 μl of AVL viral lysis buffer (Qiagen, Venlo, Nether-
lands) for RNA quantification. Remaining homogenate and supernatant were stored at -80 ˚C for
plaque assay and cytotoxicity tests, respectively.
Growth curves
Two different growth curves were performed. The first growth curved analyzed viral RNA
content in supernatant (with the advantage of observing the same well at different time points)
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and the second assessed viral titer using a homogenization protocol optimized for virus parti-
cle recovery (rationale see results and discussion).
For the first growth curve we assessed titers using three independent biological replicates.
Three wells containing four OCS were infected as described above. The medium was replaced
with 1.05 ml of supplemented NBM. Fifty microliters of supernatant were directly inactivated
in 200 μl of AVL viral lysis buffer (Qiagen). During the following four days 50 μl of supernatant
were inactivated in AVL buffer (Qiagen) and replaced by 50 μl of supplemented NBM. RNA
was extracted from the inactivated samples and eluted in half of the volume used throughout
the study to compensate the reduced sample volume.
For the second growth curve, six wells of OCS were infected as described above. On days 0,
2, and 4, three OCS from one well were mixed with 600 μl of supernatant and homogenized as
descried above, using 5000 rpm instead of 6500 rpm. To demonstrate reproducibility, on day 3
we performed this procedure using three independent biological replicates, i.e. three different
wells of OCS. One hundred microliters of homogenate were directly inactivated in 400 μl of
AVL buffer (Qiagen) for RNA quantification. The remaining homogenate was stored at -80 ˚C
and later used for plaque assay.
RNA extraction and qRT-PCR
RNA was extracted using the EZ1 Advanced robot and the EZ1 Virus Mini Kit v2.0 (Qiagen)
according to manufacturer’s recommendations. qRT-PCR for detecting TBEV was based on a
previously published protocol [15]. Primer and probe sequences amplifying a fragment of the
envelope gene (TBEE-F6: GGCTTGTGAGGCAAAAAAGAA; TBEE-R2: TCCCGTGTGTGGTTCG
ACTT; TBEE-P4: FAM-AAGCCACAGGACATGTGTACGACGCC-BHQ-1) were ordered at
Microsynth (Balgach, Switzerland). qRT-PCR was performed using TaqMan Fast Virus 1-Step
Master Mix (Thermo Fisher Scientific, Waltham, MA, USA). The qRT-PCR conditions were
as follows: 6.3 μl of 4x TaqMan Fast Virus 1-Step Master, 1 μl of each primer stock (10 μM),
0.6 μl of the probe stock (10 μM), 5 μl of sample, and RNase-free water to adjust the volume to
25 μl. PCR cycling included a reverse transcription step for 5 minutes at 50 ˚C, a polymerase
activation step for 20 seconds at 95 ˚C, and 45 cycles of two-step cycling for 3 seconds at 95 ˚C
and 30 seconds at 60 ˚C. Every sample was assessed in duplets and the average was calculated
using the arithmetic mean. Genome equivalents/ml were calculated using the following for-
mula: 10(Ct value-slope)/intercept 100/5 (for 5 μl input) with the slope being -3.296 and the inter-
cept 37.19 obtained from [16]. In order to assess the effect of premature chain termination on
quantification of viral RNA copies, a second qRT-PCR system was used. This system called
"TBEBRC" amplifies a fragment of the NS5 gene located near the 3’-end of the genome (posi-
tions 9136–9255 according to accession number U27495.1, as opposed to positions 1329–1416
for the fragment of the envelope gene). A detailed description of this second qRT-PCR system
is given in the supplementary information file.
Plaque assay
PS cell monolayers were used to assess viral titers based on a protocol of De Madrid et al. [17].
Twenty four well plates (TPP) were coated with poly-L-lysine according to manufacturer’s rec-
ommendations (Sigma Aldrich). 1.35 x 105 PS cells in 300 μl of L15 medium (Leibowitz, Bio-
chrom AG, Berlin, Germany) supplemented with 1% glutamine, 5% fetal calf serum, 1%
penicillin-streptomycin and 0.5% neomycin were seeded into each well. Successively, 200 μl of
supplemented L15 medium containing 10-fold dilutions of TBEV were prepared and used to
infect the PS cells. Each dilution was assessed in duplets and the average was calculated using
the arithmetic mean. After 4 h incubation at room temperature (RT), 400 μl of 1.5%
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carboxymethylcellulose (Sigma Aldrich) in supplemented L-15 medium was used to overlay
the suspension. After 4 days of incubation at 37 ˚C, each well was washed with 0.7 ml of phos-
phate buffered saline (PBS) and stained with 0.7 ml of naphthalene black solution (1 g naph-
thalene blue black, 60 ml glacial acetic acid, 13.6 g sodium acetate in 1 L of H2O, Sigma
Aldrich). The wells were stained between 35 and 90 minutes and washed once with 0.7 ml of
H2O. Virus titer was assessed as PFU/ml.
Immunofluorescence staining
One OCS per well was fixed in 4% formaldehyde in PBS for 90 minutes at RT and then stored
in 18% sucrose in PBS at 4 ˚C. The OCS were put in tissue freezing medium (Leica Biosystems)
and frozen at -20 ˚C inside a Jung CM 3050 S Cryostat (Leica Biosystems). The OCS were re-
sectioned into 12 μm thick slices, mounted on adhesive Histobond glasslides (Marienfeld) and
let to dry. Once dried (white appearance), the slices were submerged in PBS. Slides were
washed three times with PBS, followed by staining with TrueBlack (Biotium, Fremont, CA,
USA) to quench autofluorescence. Slides were again washed three times in PBS and incubated
overnight at 4 ˚C with primary antibodies directed against flavivirus group specific antigens
(2 μg/ml, mouse monoclonal, Millipore), Purkinje cells (PCP-2, 4 μg/ml, rabbit polyclonal,
Santa Cruz Biotechnology) or mature neurons (FOX3, 1 μg/ml, rabbit polyclonal, Millipore).
Tris buffered saline (pH 7.6) containing 0.25% bovine serum albumin was used as antibody
diluent. Sections were washed three times with PBS and then stained with the secondary anti-
bodies anti-rabbit-Alexa Fluor 488 (2 μg/ml, Life Technologies) and anti-mouse-Alexa Fluor
594 (1 μg/ml, Jackson ImmunoResearch, West Grove, PA, USA) for 60 minutes at RT in the
dark. The OCS were washed three times with PBS and mounted with VectaShield containing
Dapi (ReactoLab, Servion, Switzerland). Images were acquired on a Zeiss Observer Z1 using
the ZEN 2.3 software and the MosaiX table for scanning large tissue sections (Zeiss, Oberko-
chen, Germany).
Cytotoxicity test
To detect cytotoxicity of the compounds alone or in combination with TBEV infection, we
measured lactate dehydrogenase (LDH) release into culture supernatants using the LDH Cyto-
toxicity Assay Kit (Pierce, Thermo Fisher). The manufacturer’s recommendations were strictly
followed and each supernatant was assessed in triplicates. For cytotoxicity testing of the com-
pounds without TBEV infection, OCS were treated with specified concentrations of nucleoside
analogues following the same procedure as TBEV-infected OCS. Briefly, 100 μl of the nucleo-
side analogue in culture medium was added in droplets on top of the OCS and 900 μl was
added below the insert. DMSO without the nucleoside analogues was used as control. This was
incubated for 1 hr with a CO2 bag, followed by a complete medium change containing the
nucleoside analogue and incubation for 72 hrs with a new CO2 bag.
Absorbance was measured with a GloMax Luminometer (Promega, Madison, WI, USA) at
490 nm and at 600 nm (background noise).
Statistical analysis
A two-sided, unpaired student’s t-test was applied to assess statistical significance comparing
viral titer reduction and cytotoxicity during TBEV infection by nucleoside analogues using the
Bonferroni correction (α = 0.0125, n = 3). Calculations were performed using Microsoft Office
Excel 2016.
Evaluation of antivirals in organotypic cultures
PLOS ONE | https://doi.org/10.1371/journal.pone.0205294 October 9, 2018 5 / 13
Results and discussion
Four nucleoside analogues were investigated for their inhibitory effect on the replication of
TBEV strain Hypr in rat OCS. OCS have the advantage of comprising the entire cell commu-
nity with the conserved natural structure occurring in the cerebellum of suckling Wistar rats.
Ribavirin, 2’-CMA, 2’-CMC and 7-deaza-2’-CMA were tested at a concentration of 50 μM
equivalent to the study of Eyer et al. [8]. OCS were infected with 105 PFU of TBEV strain
Hypr. First, growth curves were established to determine the ideal harvesting time point (Fig
1). TBEV RNA content was assessed during four consecutive days in supernatant of three
independent biological replicates. The sampling time points in Fig 1 do not exceed 4 days post
infection, since a medium change necessary at latest on day 4 post infection would have
implied an important impact on the culture system, including the removal of viral particles
present in the medium. Based on these results, the samples for all subsequent experiments
were harvested three days post infection. In a preliminary study, we observed that 3 days after
infection with 105 PFU/ml, TBEV titers are considerably higher in homogenized OCS than in
supernatant (S1 Fig). Therefore, in the present study a mixture of OCS and supernatant (3
OCS in 600 μl of medium) was homogenized and then used for assessing TBEV replication.
Fig 1. Growth curve of TBEV strain Hypr in OCS infected with 105 PFU / ml and determined by qRT-PCR.
Samples were taken from supernatant. Bars show arithmetic mean of three independent biological replicates and error
bars indicate the standard deviation (n = 3). GE = genome equivalents.
https://doi.org/10.1371/journal.pone.0205294.g001
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TBEV titer reduction was analyzed by qRT-PCR, plaque assay and immunofluorescence
analysis.
Inhibition of TBEV replication
Fig 2 shows the effect of the test compounds on TBEV titer as determined by plaque assay (Fig
2A) and RNA content as genome equivalents (GE) assessed by qRT-PCR (Fig 2B) in three
independent biological replicates. The nucleoside analogues 2’-CMA and 7-deaza-2’-CMA
presented with the highest potential to reduce TBEV titers and RNA content. qRT-PCR
revealed a 75-80-fold decrease in TBEV GE compared to mock treated OCS (DMSO;
p = 0.0012 for 2’-CMA and p = 0.00014 for 7-deaza-2’-CMA), while TBEV titers measured by
plaque assay were reduced by approximately 103-fold (p = 0.0004 for 2’-CMA and p = 0.0002
for 7-deaza-2’-CMA). In contrast, 2’-CMC exhibited only a weak anti-TBEV effect with a 3
fold decrease in GE (p = 0.0084) and TBEV titer decrease of about 10-fold (statistically not sig-
nificant). Ribavirin had no significant effects on TBEV replication with results comparable to
DMSO treated controls. Interestingly, the inhibitory effect of the nucleoside analogues was
more pronounced in TBEV titers as compared to the measured RNA content. It is known, that
the tested compounds inhibit the viral RdRp by sterically hindering the polymerase from
incorporating more nucleosides, which results in premature chain termination and small
TBEV RNA fragments starting from the 5’-terminus. The qRT-PCR we performed in Fig 2B
Fig 2. Reduction of TBEV titers by the specified nucleoside analogues measured in homogenate. OCS were infected with
105 PFU of TBEV strain Hypr and treated with 50 μM of each compound. TBEV titers were measured by plaque assay (A) and
qRT-PCR (B) three days post infection. 50 μl DMSO were added as mock treatment. The detection limit of the plaque assay
was 1.4 log10 PFU / ml (thick black line). Bars show arithmetic mean of three independent biological replicates and error bars
indicate the standard deviation (n = 3). PFU = plaque forming unit, GE = genome equivalents, 2’-CMA = 2’-C-
methyladenosine, 2’-CMC = 2’-C-methylcytidine, 7-deaza-2’-CMA = 7-deaza-2’-C-methyladenosine, DMSO = dimethyl
sulfoxide, ND = not detected,  = p-value< 0.0125,  = p-value< 0.001.
https://doi.org/10.1371/journal.pone.0205294.g002
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used primers close to the 5’-terminus, thus theoretically able to detect the accumulation of pre-
maturely terminated RNA fragments, which could be the reason for the distorted TBEV GE:
PFU ratio. However, this effect was equally pronounced, regardless of whether a fragment near
the 3’-terminus (1392–1416) or the 5’-terminus (9136–9255, according to accession number
U39292.1) was amplified (S2 and S3 Figs and S1 Text). In addition to premature chain termi-
nation, 2’-CMA and 7-deaza-2’-CMA might have an additional mode of action. Such an effect
has been documented for Ribavirin and hepatitis C virus on hepatoma cells. Ortega-Prieto
et al. described, that Ribavirin reduced the specific infectivity of hepatitis C virus by induction
of lethal mutagenesis, a process yielding a higher GE:PFU ratio, as observed in this manuscript
[18].
Studies published by Eyer et al. based on the same nucleoside analogues, 2’-CMA, 2’-CMC
and 7-deaza-2’-CMA, describe a TBEV titer reduction of 104 to108- fold in vitro when applied
on PS and UKF-NB-4 cells and titer reduction of 105-fold (7-deaza-2’-CMA), when applied in
vivo to treat experimentally infected mice [8, 10]. The smaller reduction can be explained by
the lower viral titer observed in OCS. Generally, the number of permissive cells in OCS is
lower than in cell lines. Furthermore, a substantial amount of virus in the OCS was lost
through the homogenization process. We observed, that homogenization at high speed
resulted in accumulation of tissue lipids as a film on top of the aqueous solution. This lipid
layer was excluded in further manipulations of the samples lowering the TBEV titers. Since the
TBEV titer obtained by plaque assay of the 7-deaza-2’-CMA treated OCS was below detection
limit, the detected inhibiting effect of the compound might be an underestimation. In an addi-
tional growth curve we measured optimized homogenate (using 5000 rpm instead of 6500
rpm) with qRT-PCR and plaque assay (Fig 3). For each time point we homogenized contents
Fig 3. Repetition of the growth curve of TBEV strain Hypr applying an optimized homogenization procedure.
Samples were taken from homogenate and TBEV titers were assessed by plaque assay (A) and qRT-PCR (B) three days
post infection. Bars show either single data points or in case of day 3 the arithmetic mean of three independent
biological replicates with error bars indicating the standard deviation. PFU = plaque forming unit, GE = genome
equivalents.
https://doi.org/10.1371/journal.pone.0205294.g003
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of one well and on day 3 we used three independent biological replicates (i.e. three different
wells of OCS) to assess reproducibility. We retrieved on average 25 times more PFU and 7
times more GE. These results prove that a substantial amount of the viral RNA was associated
and lost with the lipid layer in the homogenization process used for this study.
In comparison to Eyer et al. in PS cells, we found a less profound reduction of TBEV titers
in OCS following treatment with 2’-CMC. Since a reduction of cell viability was observed in
PS cells treated with 50 μM 2’-CMC, the amount in virus titer reduction could be due to cell
toxicity related effects [8]. We confirmed the findings related to Ribavirin by Eyer et al. and
revealed that at a concentration of 50 μM, Ribavirin exerted no influence on TBEV replication.
To gain a visual impression we localized TBEV in OCS by immunofluorescence. OCS were
stained for TBEV using a red fluorescent dye and for two abundant cell types present in the
OCS, namely Purkinje cells and mature neurons in green (Fig 4 for Purkinje cells and S4 Fig
for mature neurons). Similar to observations made with the TBEV model virus Langat [12],
TBEV partially co-localized within Purkinje cells, the largest neurons present in the cerebellum
(see S5 Fig for a close-up view). As expected, in OCS treated with 2’-CMA and 7-deaza-2’-
CMA no TBEV could be detected, whereas in OCS treated with 2’-CMC and Ribavirin the
fluorescent signal for TBEV was comparable to the controls. In summary, the immunofluores-
cence staining corroborates our previous findings and proves successful infection and replica-
tion of TBEV in OCS, as well as pronounced inhibition of viral infection and replication by 2’-
CMA and 7-deaza-2’-CMA.
Cytotoxicity of nucleoside analogues in OCS
The cytotoxicity profiles of Ribavirin, 2’-CMA, 2’-CMC and 7-deaza-2’-CMA were evaluated
in uninfected (Fig 5A and 5B) and TBEV infected OCS (Fig 5C) by examining the culture
supernatant for presence of LDH, a common marker for tissue damage. Cytotoxicity of each
nucleoside analogue at a concentration of 50 μM on uninfected OCS was generally low and
comparable to the DMSO control (Fig 5A). Since 2’-CMA and 7-deaza-2’-CMA exhibited the
best antiviral activity against TBEV titers, cytotoxicity was also assessed for higher concentra-
tions (Fig 5B). No difference was observed in OCS treated with 50 μM and 100 μM of 2’-CMA
and 7-deaza-2’-CMA. LDH concentrations doubled in OCS treated with 200 μM for both
compounds and reached a peak at 500 μM. The reduced signal measured at 1000 μM could be
explained by an early release of most LDH within the first hour, which was lost upon the fol-
lowing medium change (Fig 5B). In infected OCS, LDH release closely correlated to observed
TBEV titers and is therefore likely attributable to the cytopathic effect of the virus (Fig 5C).
Taking together, these findings further substantiate, that, 2’-CMA and 7-deaza-2’-CMA exhibit
a considerable inhibitory effect on TBEV replication in rat OCS at 50 μM and are likely safe at
concentrations up to 100 μM. Compared to Eyer et al., we did not observe a cytotoxic effect of
2’-CMC higher than the DMSO control in uninfected OCS. This could explain the discrepancy
observed in the effect of 2’-CMC on TBEV titers in OCS and PS and UKF-NB4 cell lines.
Conclusions
Rat OCS represent an ideal in vitro approach to study antivirals’ inhibitory effect on neuro-
tropic TBEV replication in target tissue. 2’-CMA and especially 7-deaza-2’-CMA presented
with excellent cytotoxicity profiles and substantial inhibitory effect on TBEV replication, thus
identifying them as promising candidates for future evaluations of therapeutic interventions
against TBEV infections.
Future steps encompass testing whether OCS are suitable to study antivirals against other
neurotropic flaviviruses and assessing comparability to in vivo experiments.
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Supporting information
S1 Fig. Comparison of TBEV titer in supernatant and homogenate. Titers were assessed by
plaque assay. Bars show the arithmetic mean of two independent biological replicates with
error bars indicating the standard deviation. Supe = supernatant, HG = homogenate.
(TIFF)
S2 Fig. Comparison of TBEV RNA content using two different primer pairs. TBEE primer
detect TBEV RNA close to the 5’-end, whereas TBEBRC measure RNA close to the 3’-end.
Bars show the arithmetic mean of three independent biological replicates with error bars indi-
cating the standard deviation. GE = genome equivalents.
(TIFF)
S3 Fig. Ten-fold serial dilutions of untreated TBEV RNA from a PS cell culture measured
by the two different primer pairs TBEE and TBEBRC. Bars show the arithmetic mean of 2
dependent biological replicates. GE = genome equivalents, ND = not detected.
(TIFF)
S4 Fig. Immunofluorescence analysis of OCS infected with 105 PFU / ml of TBEV strain
Hypr and treated with the specified nucleoside analogue at 50 μM; 3 days post infection.
Blue = Dapi staining, red = TBEV and green = mature neurons. 2’-CMA = 2’-C-methyladeno-
sine, 2’-CMC = 2’-C-methylcytidine, 7-deaza-2’-CMA = 7-deaza-2’-C-methyladenosine,
Fig 4. Immunofluorescence analysis of OCS infected with 105 PFU / ml of TBEV strain Hypr and treated with the specified nucleoside analogue at
50 μM; 3 days post infection. Blue = Dapi staining, red = TBEV and green = Purkinje cells. 2’-CMA = 2’-C-methyladenosine, 2’-CMC = 2’-C-methylcytidine,
7-deaza-2’-CMA = 7-deaza-2’-C-methyladenosine, DMSO = dimethyl sulfoxide. Scale bars are 1 mm long.
https://doi.org/10.1371/journal.pone.0205294.g004
Fig 5. Cytotoxicity assessed by measuring LDH (Lactate dehydrogenase) release into supernatant of OCS 3 days after treatment with specified nucleoside
analogues. (A) At 50 μM, between 50 and 1000 μM (B) and of TBEV infected OCS treated with nucleoside analogues at 50 μM (C). Bars show either single data points
(A and B) or the arithmetic mean of 3 independent biological replicates with error bars indicating the standard deviation (C). 2’-CMA = 2’-C-methyladenosine, 2’-
CMC = 2’-C-methylcytidine, 7-deaza-2’-CMA = 7-deaza-2’-C-methyladenosine, DMSO = dimethyl sulfoxide, ns = not statistically significant.
https://doi.org/10.1371/journal.pone.0205294.g005
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DMSO = dimethyl sulfoxide.
(TIFF)
S5 Fig. Close-up view of immunofluorescence analysis of OCS infected with 105 PFU / ml
of TBEV strain Hypr to illustrate co-localization with Purkinje cells. Blue = Dapi staining,
red = TBEV and green = Purkinje cells.
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S1 Text. Description of additional experiments depicted in S2 and S3 Figs.
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